Denali Therapeutics Inc. DNLI
Set alert
18.94 USD -0.38 -1.97%
At close · Oct 30
19.00 +0.06 +0.32%
After hours · Oct 30, 4:59 PM ET
18.64 Day range 19.63
14.41 52-week range 27.21
- YTD
- +14.72%
- 1 year
- +15.63%
- Open
- 19.25
- Prev close
- 19.32
- Mkt cap
- 3.03B
- Vol
- 1.31M
- Avg vol
- 1.57M
- EPS
- -2.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.64
- High
- 19.63
- Forward P/E
- -7.84
- Beta
- 1.02
- Short ratio
- 7.76
- Inst. own
- 101.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 20.76
- 200-d avg
- 21.23
- 1y target
- 35.50
1D chart
Signals (44)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | 3:55 PM | 2 days ago |
| RSI: Overbought | 3:49 PM | 2 days ago |
| RSI: Overbought | 3:47 PM | 2 days ago |
| MACD: Buy Signal | 3:45 PM | 2 days ago |
| MACD: Sell Signal | 3:42 PM | 2 days ago |
| RSI: Overbought | 3:35 PM | 2 days ago |
| MACD: Buy Signal | 3:33 PM | 2 days ago |
| MACD: Sell Signal | 3:29 PM | 2 days ago |
| MACD: Buy Signal | 3:26 PM | 2 days ago |
| MACD: Sell Signal | 3:18 PM | 2 days ago |
| RSI: Overbought | 3:10 PM | 2 days ago |
| RSI: Overbought | 3:07 PM | 2 days ago |
| SMA: Bullish | 2:57 PM | 2 days ago |
| SMA: Bearish | 2:49 PM | 2 days ago |
| SMA: Bullish | 2:48 PM | 2 days ago |
| MACD: Buy Signal | 2:47 PM | 2 days ago |
| MACD: Sell Signal | 2:44 PM | 2 days ago |
| RSI: Oversold | 2:29 PM | 2 days ago |
| MACD: Buy Signal | 2:27 PM | 2 days ago |
| RSI: Oversold | 2:15 PM | 2 days ago |
| RSI: Oversold | 2:12 PM | 2 days ago |
| MACD: Sell Signal | 2:10 PM | 2 days ago |
| MACD: Buy Signal | 2:07 PM | 2 days ago |
| MACD: Sell Signal | 1:55 PM | 2 days ago |
| SMA: Bearish | 1:53 PM | 2 days ago |
| MACD: Buy Signal | 1:41 PM | 2 days ago |
| RSI: Oversold | 1:26 PM | 2 days ago |
| RSI: Oversold | 1:13 PM | 2 days ago |
| MACD: Sell Signal | 1:11 PM | 2 days ago |
| MACD: Buy Signal | 12:59 PM | 2 days ago |
| MACD: Sell Signal | 12:51 PM | 2 days ago |
| SMA: Bearish | 12:48 PM | 2 days ago |
| SMA: Bearish | 12:48 PM | 2 days ago |
| MACD: Buy Signal | 12:36 PM | 2 days ago |
| MACD: Sell Signal | 12:32 PM | 2 days ago |
| SMA: Bullish | 12:17 PM | 2 days ago |
| MACD: Buy Signal | 12:17 PM | 2 days ago |
| MACD: Sell Signal | 12:12 PM | 2 days ago |
| MACD: Buy Signal | 11:53 AM | 2 days ago |
| RSI: Oversold | 11:47 AM | 2 days ago |
| RSI: Oversold | 11:43 AM | 2 days ago |
| SMA: Bearish | 11:32 AM | 2 days ago |
| MACD: Sell Signal | 11:12 AM | 2 days ago |
| SMA: Bullish | 10:36 AM | 2 days ago |
Key statistics
- Market cap
- 3.03B
- Enterprise value
- 2.42B
- Trailing P/E
- 0.00
- Forward P/E
- -7.84
- PEG ratio
- 0.00
- Price / sales
- 840.04
- Price / book
- 3.62
- EPS (TTM)
- -2.84
- Beta
- 1.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.60M
- Revenue growth
- 0.00%
- Free cash flow
- -268.53M
- Total cash
- 710.47M
- Total debt
- 37.69M
- Return on equity
- -54.93%
- Shares outstanding
- 159.85M
- Short % of float
- 10.21%
- 50-day average
- 20.76
- 200-day average
- 21.23
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.50 +87.4% upside
Now 18.94
- Target (low)
- 23.00
- Target (mean)
- 35.50
- Target (high)
- 42.00
Ratings (0m) 20 19 buy · 1 hold · 0 sell
- Strong buy2
- Buy17
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.36666.
Financials — quick view
DNLI Revenue — quarterly 3.60M
DNLI Net income — quarterly -127.55M
DNLI EPS — quarterly -0.68
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.3222 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.51305 | -0.68 | -0.17 | -32.54% |
| May 7, 2026 | Mar 31, 2026 | -0.73 | -0.69 | +0.04 | +5.48% |
| Feb 26, 2026 | Dec 31, 2025 | -0.75 | -0.73 | +0.02 | +2.67% |
| Nov 6, 2025 | Sep 30, 2025 | -0.76 | -0.74 | +0.02 | +2.63% |
| Aug 11, 2025 | Jun 30, 2025 | -0.74 | -0.72 | +0.02 | +2.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 25, 2026 | B. Riley Securities | main | Buy | Buy |
| Aug 7, 2026 | UBS | main | Buy | Buy |
| Jul 23, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jul 16, 2026 | Deutsche Bank | main | Buy | Buy |
| May 26, 2026 | Morgan Stanley | main | Overweight | Overweight |
| May 14, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- denalitherapeutics.com
News
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
- Denali Therapeutics Q2 2026 Earnings Call Transcript
- Engineers Gate Manager LP Boosts Stock Position in Denali Therapeutics Inc. $DNLI
- WINTON GROUP Ltd Decreases Position in Denali Therapeutics Inc. $DNLI
- Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT)
- Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLI
- B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35
- DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Your note
Sign in to keep a note on DNLI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 2, 2026 | 0 |
| CHIN PETER SCOTT | Officer | Sale | Sep 3, 2026 | 204,538 |
| FLATLEY JAY T | Director | Stock Award(Grant) | Jun 2, 2026 | 358,941 |
| HO CAROLE | Officer | Sale | Aug 12, 2025 | 424,804 |
| KROGNES STEVE E | Director | Stock Award(Grant) | Jun 2, 2026 | 819,999 |
| SATO VICKI LEE | Director | Sale | Jan 1, 2025 | 107,976 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.12% | 16,178,963 | 306.43M | Jun 29, 2026 |
| Blackrock Inc. | 8.77% | 14,026,413 | 265.66M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 7.48% | 11,960,230 | 226.53M | Jun 29, 2026 |
| State Street Corporation | 4.41% | 7,049,304 | 133.51M | Jun 29, 2026 |
| Temasek Holdings (Private) Ltd | 4.39% | 7,012,974 | 132.83M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.05% | 6,477,057 | 122.68M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 3.11% | 4,966,700 | 94.07M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.68% | 4,288,391 | 81.22M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.39% | 3,813,515 | 72.23M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.94% | 3,097,183 | 58.66M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.91% | 3,055,331 | 57.87M | Sep 29, 2026 |
| VANGUARD WORLD FUND-Vanguard U.S. Growth Fund | 1.90% | 3,037,857 | 57.54M | May 30, 2026 |